Angelika Hammerer-Lercher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Angelika Hammerer-Lercher has a total of 169 co-authors. Here are the top co-authors by number of shared publications:
- Peter Neyer
Institute of Laboratory Medicine, Kantonsspital Aarau, Aarau, Switzerland
5 shared publications Gabrielle Huré
Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel, Spitalstrasse 2, 4056 Basel
3 shared publicationsAndreas Mueller
Department of Orthopedics and Trauma Surgery, University Hospital Basel, University of Basel , Petersgraben 4, 4031 Basel
2 shared publications- Christian Puelacher
Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel , Spitalstrasse 2, 4056 Basel, Switzerland
2 shared publications - Christoph Kindler
Chefarzt Klinik für Anästhesie, Kantonsspital Aarau, Switzerland
2 shared publications - Daniel Bolliger
Clinic for Anesthesia, Intermediate Care, Prehospital Emergency Medicine and Pain Therapy, University Hospital Basel, Basel, Switzerland
2 shared publications
Latest Publications
- Open Access
- 18 February 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (2) , 255
Stability Assessment of Intravenous Iron–Carbohydrate Complexes in Commercial All-in-One Parenteral Nutrition: Potential for Therapeutic Iron Dose Admixing
Background/Objectives: Iron deficiency and associated iron deficiency anaemia represent a major global health burden. Parenteral nutrition (PN) patients are at increased risk of iron deficiency due to inadequate iron supplementation. Currently, iron is added to all-in-one (AIO) PN mostly as low-dose ferric chloride in trace element solutions, limited to 1–2 mg in adults, to ensure emulsion stability and prevent lipid peroxidation. The objective of this study was to evaluate the compatibility and stability of selected, widely used complex-bound iron products added to AIO PN over a 48 h period. Methods: Ferric carboxymaltose and iron sucrose were added as non-biological complex intravenous iron oxide carbohydrate products to two different commercial AIO PN admixtures for adults. The iron concentrations used were 100 and 400 mg/L (1.79 and 7.16 mmol/L), corresponding to approximately 200 mg (3.58 mmol) of iron dose per PN bag. Free and complex-bound iron were separated using 100 kDa dialysis tubes. Free and complex-bound iron were assessed at 4, 24, and 48 h after admixing. pH was measured before and at 0, 4, 24, and 48 h after admixture. Iron quantification was performed by inductively coupled plasma mass spectrometry (ICP-MS). Results: No significant changes in complex-bound iron concentration were observed over the 48 h incubation period (p-value = 0.449; estimate 0.060 mg/L per h, 95% CI −0.089, 0.201 mg/L per h). The concentration of free iron was very low and increased only slightly over time. Iron recovery ranged from 95.8% to 103.9%. The addition of the alkaline iron sucrose significantly increased the pH of the AIO admixture (p-value = 0.033), whereas the addition of ferric carboxymaltose did not affect the pH (p-value = 0.351). After the initial increase, the pH of all conditions remained stable over the 48 h incubation period (p-value = 0.07). Conclusions: Ferric carboxymaltose demonstrated stable intravenous iron admixtures within the PN formulations tested. Before the clinical application of these findings, further studies should specifically evaluate the lipid peroxidation and stability of the lipid emulsions, the most sensitive and important PN compatibility and safety characteristics of AIO PN.
- 18 February 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (2) , 255
Open AccessStability Assessment of Intravenous Iron–Carbohydrate Complexes in Commercial All-in-One Parenteral Nutrition: Potential for Therapeutic Iron Dose Admixing
Background/Objectives: Iron deficiency and associated iron deficiency anaemia represent a major global health burden. Parenteral nutrition (PN) patients are at increased risk of iron deficiency due to inadequate iron supplementation. Currently, iron is added to all-in-one (AIO) PN mostly as low-dose ferric chloride in trace element solutions, limited to 1–2 mg in adults, to ensure emulsion stability and prevent lipid peroxidation. The objective of this study was to evaluate the compatibility and stability of selected, widely used complex-bound iron products added to AIO PN over a 48 h period. Methods: Ferric carboxymaltose and iron sucrose were added as non-biological complex intravenous iron oxide carbohydrate products to two different commercial AIO PN admixtures for adults. The iron concentrations used were 100 and 400 mg/L (1.79 and 7.16 mmol/L), corresponding to approximately 200 mg (3.58 mmol) of iron dose per PN bag. Free and complex-bound iron were separated using 100 kDa dialysis tubes. Free and complex-bound iron were assessed at 4, 24, and 48 h after admixing. pH was measured before and at 0, 4, 24, and 48 h after admixture. Iron quantification was performed by inductively coupled plasma mass spectrometry (ICP-MS). Results: No significant changes in complex-bound iron concentration were observed over the 48 h incubation period (p-value = 0.449; estimate 0.060 mg/L per h, 95% CI −0.089, 0.201 mg/L per h). The concentration of free iron was very low and increased only slightly over time. Iron recovery ranged from 95.8% to 103.9%. The addition of the alkaline iron sucrose significantly increased the pH of the AIO admixture (p-value = 0.033), whereas the addition of ferric carboxymaltose did not affect the pH (p-value = 0.351). After the initial increase, the pH of all conditions remained stable over the 48 h incubation period (p-value = 0.07). Conclusions: Ferric carboxymaltose demonstrated stable intravenous iron admixtures within the PN formulations tested. Before the clinical application of these findings, further studies should specifically evaluate the lipid peroxidation and stability of the lipid emulsions, the most sensitive and important PN compatibility and safety characteristics of AIO PN.
- Top Cited Papers
- 30 January 2026
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (12) , 1470-1483
Peri-operative myocardial infarction/injury after non-cardiac surgery: association between cardiologist evaluation and outcomes
Background and Aims: Peri-operative myocardial infarction/injury (PMI) is a common cardiac complication following non-cardiac surgery. It remains unclear whether involvement of cardiologists in the management of patients developing PMI improves outcomes. Methods: This multicentre, prospective study included high-risk patients undergoing non-cardiac surgery, eligible for the institutional PMI active surveillance and response programme. Due to staffing constraints, cardiologist evaluation of patients with PMI was inconsistently available on weekends, on public holidays, or when care for more urgent patients had to be prioritized, allowing a comparison between patients receiving cardiologist evaluation and those who did not. The primary endpoint was major adverse cardiac events, defined as a composite of cardiovascular death, myocardial infarction, acute heart failure, and life-threatening arrhythmia at 365 days. The secondary endpoint was all-cause death at 365 days. Cox proportional hazards models were used to evaluate the association between cardiologist evaluation and outcomes. Results: Among 14 294 patients, 1048 developed PMI and were eligible for this analysis, of whom 614 patients (58.6%) received post-operative cardiologist evaluation. Baseline characteristics were similar between groups. After adjustment, cardiologist evaluation was independently associated with lower risk of major adverse cardiac events (adjusted hazard ratio .54, P = .001) and all-cause death (adjusted hazard ratio .65, P = .037) at 365 days. Sensitivity analyses confirmed these findings. Patients receiving cardiology evaluation were more likely to undergo non-invasive cardiac imaging and to receive dual antiplatelet and statin therapy. Conclusions: Cardiologist evaluation of patients with PMI following major non-cardiac surgery was associated with a reduced risk of major adverse cardiac events and all-cause mortality at 365 days after surgery, suggesting that interdisciplinary management may improve post-operative outcomes.
- 30 January 2026
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (12) , 1470-1483
Top Cited PapersPeri-operative myocardial infarction/injury after non-cardiac surgery: association between cardiologist evaluation and outcomes
Background and Aims: Peri-operative myocardial infarction/injury (PMI) is a common cardiac complication following non-cardiac surgery. It remains unclear whether involvement of cardiologists in the management of patients developing PMI improves outcomes. Methods: This multicentre, prospective study included high-risk patients undergoing non-cardiac surgery, eligible for the institutional PMI active surveillance and response programme. Due to staffing constraints, cardiologist evaluation of patients with PMI was inconsistently available on weekends, on public holidays, or when care for more urgent patients had to be prioritized, allowing a comparison between patients receiving cardiologist evaluation and those who did not. The primary endpoint was major adverse cardiac events, defined as a composite of cardiovascular death, myocardial infarction, acute heart failure, and life-threatening arrhythmia at 365 days. The secondary endpoint was all-cause death at 365 days. Cox proportional hazards models were used to evaluate the association between cardiologist evaluation and outcomes. Results: Among 14 294 patients, 1048 developed PMI and were eligible for this analysis, of whom 614 patients (58.6%) received post-operative cardiologist evaluation. Baseline characteristics were similar between groups. After adjustment, cardiologist evaluation was independently associated with lower risk of major adverse cardiac events (adjusted hazard ratio .54, P = .001) and all-cause death (adjusted hazard ratio .65, P = .037) at 365 days. Sensitivity analyses confirmed these findings. Patients receiving cardiology evaluation were more likely to undergo non-invasive cardiac imaging and to receive dual antiplatelet and statin therapy. Conclusions: Cardiologist evaluation of patients with PMI following major non-cardiac surgery was associated with a reduced risk of major adverse cardiac events and all-cause mortality at 365 days after surgery, suggesting that interdisciplinary management may improve post-operative outcomes.
- 18 October 2025
- Published by Elsevier in International Journal of Medical Informatics
- Vol. 206, 106161
Interpretable type 2 diabetes incidence prediction with AutoScore: A model based on standard clinical parameters
- 18 October 2025
- Published by Elsevier in International Journal of Medical Informatics
- Vol. 206, 106161
Interpretable type 2 diabetes incidence prediction with AutoScore: A model based on standard clinical parameters
- Open Access
- 6 July 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (13) , 1720
Assessing the Reliability of D-Dimer Measurement in EDTA Plasma: A Comparison to the Established Citrate Method
Background: D-dimer determined in citrated plasma is a well-established and efficient biomarker, particularly for ruling out venous thromboembolism. In certain clinical settings, the availability of citrated plasma may pose challenges when not readily available. To address this issue, we investigated the feasibility of using ethylenediaminetetraacetic acid (EDTA) plasma as an alternative specimen for D-dimer measurement. Methods: Our study evaluated anonymized plasma samples (n = 99, for both citrate and EDTA) using the INNOVANCE® D-dimer assay, an automated particle-enhanced immunoassay, and the INNOVANCE® LOCI hs D-dimer assay, leveraging the luminescent oxygen channeling assay (LOCI) method. Results: The assays demonstrated a correlation of r ≥ 0.97 (95% CI 0.96 to 0.98) within citrated plasma and maintained a similar correlation r ≥ 0.96 (95% CI 0.94 to 0.97) between citrate and EDTA plasma upon correction for the dilution effect of the sodium citrate solution. Conclusions: These results indicate that the utilization of EDTA instead of citrate plasma is feasible and may provide similar diagnostic information. However, the observed variance could have an impact on clinical interpretation and risk assessment. Therefore, future studies are needed to confirm the results and, if necessary, determine cut-off values and clinical performance.
- 6 July 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (13) , 1720
Open AccessAssessing the Reliability of D-Dimer Measurement in EDTA Plasma: A Comparison to the Established Citrate Method
Background: D-dimer determined in citrated plasma is a well-established and efficient biomarker, particularly for ruling out venous thromboembolism. In certain clinical settings, the availability of citrated plasma may pose challenges when not readily available. To address this issue, we investigated the feasibility of using ethylenediaminetetraacetic acid (EDTA) plasma as an alternative specimen for D-dimer measurement. Methods: Our study evaluated anonymized plasma samples (n = 99, for both citrate and EDTA) using the INNOVANCE® D-dimer assay, an automated particle-enhanced immunoassay, and the INNOVANCE® LOCI hs D-dimer assay, leveraging the luminescent oxygen channeling assay (LOCI) method. Results: The assays demonstrated a correlation of r ≥ 0.97 (95% CI 0.96 to 0.98) within citrated plasma and maintained a similar correlation r ≥ 0.96 (95% CI 0.94 to 0.97) between citrate and EDTA plasma upon correction for the dilution effect of the sodium citrate solution. Conclusions: These results indicate that the utilization of EDTA instead of citrate plasma is feasible and may provide similar diagnostic information. However, the observed variance could have an impact on clinical interpretation and risk assessment. Therefore, future studies are needed to confirm the results and, if necessary, determine cut-off values and clinical performance.
- Open Access
- 22 May 2025
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 63 (10) , 2093-2103
False-positive cardiac troponin I values due to macrotroponin in healthy athletes after COVID-19
Objectives: Cardiac troponins (cTn) are used to detect and quantify acute cardiomyocyte injury. In patients presenting with symptoms that could indicate myocarditis, elevated cTn concentrations typically mandate cardiac catheterization and heart muscle biopsy or cardiac magnetic resonance imaging (CMR). Accordingly, increased cTn levels due to macrotroponin – a complex between patient anti-troponin autoantibodies and cTn – could lead to unnecessary and potentially harmful interventions. In athletes, ensuring cardiac health after infection like COVID-19 is critical, but the occurrence of false-positive cTn levels post-COVID-19 remains unknown. Methods: This observational study prospectively included 35 healthy athletes (aged 16–75 years; 19 females, 16 males) who underwent post-COVID check-ups during 2022–2023. Athletes’ cTn levels were measured using four different hs-cTn routine immunoassays. If discrepancies were noted between assays, further testing for macrotroponin was conducted using protein G column, sucrose gradient ultracentrifugation and anti-troponin autoantibody immunoassay. Results: Seventeen athletes had normal cTn levels across all assays, while 18 (51 %) had elevated cTn, mostly cTnI. Despite elevated cTn levels, no signs of myocarditis or other cardiac conditions were found on electrocardiography, echocardiography, or CMR. Macrotroponin was confirmed among 16 of these 18 athletes. Further, IgG anti-troponin autoantibodies correlated significantly with the levels of the two most-commonly affected assays: hs-cTnI-Siemens Atellica and hs-cTnI-Abbott Alinity. Conclusions: Post-COVID-19, nearly half of athletes showed elevated cTnI levels due to interference from macrotroponin. Awareness among physicians and laboratorians of this analytical confounder can avoid unnecessary invasive or costly diagnostic tests in athletes with false-positive cTnI levels after COVID-19.
- 22 May 2025
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 63 (10) , 2093-2103
Open AccessFalse-positive cardiac troponin I values due to macrotroponin in healthy athletes after COVID-19
Objectives: Cardiac troponins (cTn) are used to detect and quantify acute cardiomyocyte injury. In patients presenting with symptoms that could indicate myocarditis, elevated cTn concentrations typically mandate cardiac catheterization and heart muscle biopsy or cardiac magnetic resonance imaging (CMR). Accordingly, increased cTn levels due to macrotroponin – a complex between patient anti-troponin autoantibodies and cTn – could lead to unnecessary and potentially harmful interventions. In athletes, ensuring cardiac health after infection like COVID-19 is critical, but the occurrence of false-positive cTn levels post-COVID-19 remains unknown. Methods: This observational study prospectively included 35 healthy athletes (aged 16–75 years; 19 females, 16 males) who underwent post-COVID check-ups during 2022–2023. Athletes’ cTn levels were measured using four different hs-cTn routine immunoassays. If discrepancies were noted between assays, further testing for macrotroponin was conducted using protein G column, sucrose gradient ultracentrifugation and anti-troponin autoantibody immunoassay. Results: Seventeen athletes had normal cTn levels across all assays, while 18 (51 %) had elevated cTn, mostly cTnI. Despite elevated cTn levels, no signs of myocarditis or other cardiac conditions were found on electrocardiography, echocardiography, or CMR. Macrotroponin was confirmed among 16 of these 18 athletes. Further, IgG anti-troponin autoantibodies correlated significantly with the levels of the two most-commonly affected assays: hs-cTnI-Siemens Atellica and hs-cTnI-Abbott Alinity. Conclusions: Post-COVID-19, nearly half of athletes showed elevated cTnI levels due to interference from macrotroponin. Awareness among physicians and laboratorians of this analytical confounder can avoid unnecessary invasive or costly diagnostic tests in athletes with false-positive cTnI levels after COVID-19.
- 15 April 2024
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 132 (6) , 1194-1203
Association of preoperative beta-blocker use and cardiac complications after major noncardiac surgery: a prospective cohort study
- 15 April 2024
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 132 (6) , 1194-1203
Association of preoperative beta-blocker use and cardiac complications after major noncardiac surgery: a prospective cohort study
- Open Access
- 26 January 2024
- Published by Wiley in British Journal of Haematology
- Vol. 204 (5) , 2066-2070
Increased erythroferrone levels in malarial anaemia
Summary: We assessed the diagnostic potential of erythroferrone as a biomarker for iron homeostasis comparing iron deficiency cases with anaemia of inflammation and controls. The dysregulation of the hepcidin axis was observed by Latour et al. in a mouse model of malarial anaemia induced by prolonged Plasmodium infection leading to increased erythroferrone concentrations. In line with that, we found significantly higher erythroferrone levels in cases with malaria and anaemia in an African population, compared to asymptomatic controls. Therefore, our findings extend the previous ones of the mouse model, suggesting also a dysregulation of the hepcidin axis in humans, which should be further corroborated in prospective studies and may lay the basis for the development of improved treatment strategies according to ERFE concentrations in such patients.
- 26 January 2024
- Published by Wiley in British Journal of Haematology
- Vol. 204 (5) , 2066-2070
Open AccessIncreased erythroferrone levels in malarial anaemia
Summary: We assessed the diagnostic potential of erythroferrone as a biomarker for iron homeostasis comparing iron deficiency cases with anaemia of inflammation and controls. The dysregulation of the hepcidin axis was observed by Latour et al. in a mouse model of malarial anaemia induced by prolonged Plasmodium infection leading to increased erythroferrone concentrations. In line with that, we found significantly higher erythroferrone levels in cases with malaria and anaemia in an African population, compared to asymptomatic controls. Therefore, our findings extend the previous ones of the mouse model, suggesting also a dysregulation of the hepcidin axis in humans, which should be further corroborated in prospective studies and may lay the basis for the development of improved treatment strategies according to ERFE concentrations in such patients.
- Open Access
- 19 October 2023
- Published by Elsevier in Clinical Nutrition
- Vol. 42 (12) , 2475-2483
Aluminum and other chemical elements in parenteral nutrition components and all-in-one admixtures
- 19 October 2023
- Published by Elsevier in Clinical Nutrition
- Vol. 42 (12) , 2475-2483
Open AccessAluminum and other chemical elements in parenteral nutrition components and all-in-one admixtures
- Open Access
Human genetics implicates a BACH2-NRF2 axis in fetal hemoglobin activation
Human genetic studies have identified key regulators of fetal hemoglobin (HbF) expression, including BCL11A, resulting in therapeutic advances. Yet the mechanisms by which HbF expression is activated remain incompletely understood. Here, we conduct a multi-ancestry genome-wide association study of HbF levels in 28,237 individuals that identifies 131 conditionally-independent associations across 12 genomic regions. In one previously uncharacterized associated region, the high-HbF-linked causal variant, rs1010474-C, reduces BACH2 expression and elevates HbF levels. Direct perturbation or inhibition of BACH2 elevates HbF expression. Mechanistically, BACH2 restrains activation of the HbF-encoding γ -globin genes, while loss of BACH2 enhances NRF2 chromatin occupancy and promotes activation foci formation at the γ -globin genes. BACH2 and NRF2 binding motifs in the γ -globin promoters, while overlapping, can be selectively edited to activate or repress γ -globin, respectively, and function independently of BCL11A. These findings illustrate how human genetic variation continues to advance our knowledge of therapeutically-relevant regulatory mechanisms underlying HbF expression.
Open AccessHuman genetics implicates a BACH2-NRF2 axis in fetal hemoglobin activation
Human genetic studies have identified key regulators of fetal hemoglobin (HbF) expression, including BCL11A, resulting in therapeutic advances. Yet the mechanisms by which HbF expression is activated remain incompletely understood. Here, we conduct a multi-ancestry genome-wide association study of HbF levels in 28,237 individuals that identifies 131 conditionally-independent associations across 12 genomic regions. In one previously uncharacterized associated region, the high-HbF-linked causal variant, rs1010474-C, reduces BACH2 expression and elevates HbF levels. Direct perturbation or inhibition of BACH2 elevates HbF expression. Mechanistically, BACH2 restrains activation of the HbF-encoding γ -globin genes, while loss of BACH2 enhances NRF2 chromatin occupancy and promotes activation foci formation at the γ -globin genes. BACH2 and NRF2 binding motifs in the γ -globin promoters, while overlapping, can be selectively edited to activate or repress γ -globin, respectively, and function independently of BCL11A. These findings illustrate how human genetic variation continues to advance our knowledge of therapeutically-relevant regulatory mechanisms underlying HbF expression.